+Follow
JohnsonPang
No personal profile
0
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
JohnsonPang
2021-07-22
Great!
Roche in talks with FDA on Alzheimer's candidate, says CEO
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":4090043609782150,"uuid":"4090043609782150","gmtCreate":1626940777707,"gmtModify":1626945963251,"name":"JohnsonPang","pinyin":"johnsonpang","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/951587a1e65b06658f73f15d45b0f1c0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":172191102,"gmtCreate":1626942300506,"gmtModify":1703480997381,"author":{"id":"4090043609782150","authorId":"4090043609782150","authorIdStr":"4090043609782150","name":"JohnsonPang","avatar":"https://static.tigerbbs.com/951587a1e65b06658f73f15d45b0f1c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090043609782150"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172191102","repostId":"2153622308","repostType":4,"repost":{"id":"2153622308","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626938443,"share":"https://ttm.financial/m/news/2153622308?lang=&edition=fundamental","pubTime":"2021-07-22 15:20","market":"us","language":"en","title":"Roche in talks with FDA on Alzheimer's candidate, says CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2153622308","media":"Reuters","summary":"ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheime","content":"<p>ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheimer's disease with the U.S. Food and Drug Administration (FDA) as clinical trials proceed, Chief Executive Severin Schwan told reporters on Thursday.</p>\n<p>Analysts have speculated about an expedited filing for regulatory approval of gantenerumab, which could be a blockbuster if shown to work against the debilitating disease.</p>\n<p>Roche will complete a Phase-III trial of the medicine in the second half of next year, Schwan said, citing the urgency of finding a way to treat such an unmet medical need and bringing it to patients as soon as possible.</p>\n<p>\"There is a continued dialogue with the FDA. I wouldn't be able to speculate what the outcome of this dialogue will be,\" he said.</p>\n<p>\"Our trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let's keep fingers crossed,\" he added.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche in talks with FDA on Alzheimer's candidate, says CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche in talks with FDA on Alzheimer's candidate, says CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-22 15:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheimer's disease with the U.S. Food and Drug Administration (FDA) as clinical trials proceed, Chief Executive Severin Schwan told reporters on Thursday.</p>\n<p>Analysts have speculated about an expedited filing for regulatory approval of gantenerumab, which could be a blockbuster if shown to work against the debilitating disease.</p>\n<p>Roche will complete a Phase-III trial of the medicine in the second half of next year, Schwan said, citing the urgency of finding a way to treat such an unmet medical need and bringing it to patients as soon as possible.</p>\n<p>\"There is a continued dialogue with the FDA. I wouldn't be able to speculate what the outcome of this dialogue will be,\" he said.</p>\n<p>\"Our trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let's keep fingers crossed,\" he added.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHVF":"Roche Holding Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153622308","content_text":"ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheimer's disease with the U.S. Food and Drug Administration (FDA) as clinical trials proceed, Chief Executive Severin Schwan told reporters on Thursday.\nAnalysts have speculated about an expedited filing for regulatory approval of gantenerumab, which could be a blockbuster if shown to work against the debilitating disease.\nRoche will complete a Phase-III trial of the medicine in the second half of next year, Schwan said, citing the urgency of finding a way to treat such an unmet medical need and bringing it to patients as soon as possible.\n\"There is a continued dialogue with the FDA. I wouldn't be able to speculate what the outcome of this dialogue will be,\" he said.\n\"Our trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let's keep fingers crossed,\" he added.","news_type":1},"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":172191102,"gmtCreate":1626942300506,"gmtModify":1703480997381,"author":{"id":"4090043609782150","authorId":"4090043609782150","authorIdStr":"4090043609782150","name":"JohnsonPang","avatar":"https://static.tigerbbs.com/951587a1e65b06658f73f15d45b0f1c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090043609782150"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172191102","repostId":"2153622308","repostType":4,"repost":{"id":"2153622308","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626938443,"share":"https://ttm.financial/m/news/2153622308?lang=&edition=fundamental","pubTime":"2021-07-22 15:20","market":"us","language":"en","title":"Roche in talks with FDA on Alzheimer's candidate, says CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2153622308","media":"Reuters","summary":"ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheime","content":"<p>ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheimer's disease with the U.S. Food and Drug Administration (FDA) as clinical trials proceed, Chief Executive Severin Schwan told reporters on Thursday.</p>\n<p>Analysts have speculated about an expedited filing for regulatory approval of gantenerumab, which could be a blockbuster if shown to work against the debilitating disease.</p>\n<p>Roche will complete a Phase-III trial of the medicine in the second half of next year, Schwan said, citing the urgency of finding a way to treat such an unmet medical need and bringing it to patients as soon as possible.</p>\n<p>\"There is a continued dialogue with the FDA. I wouldn't be able to speculate what the outcome of this dialogue will be,\" he said.</p>\n<p>\"Our trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let's keep fingers crossed,\" he added.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche in talks with FDA on Alzheimer's candidate, says CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche in talks with FDA on Alzheimer's candidate, says CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-22 15:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheimer's disease with the U.S. Food and Drug Administration (FDA) as clinical trials proceed, Chief Executive Severin Schwan told reporters on Thursday.</p>\n<p>Analysts have speculated about an expedited filing for regulatory approval of gantenerumab, which could be a blockbuster if shown to work against the debilitating disease.</p>\n<p>Roche will complete a Phase-III trial of the medicine in the second half of next year, Schwan said, citing the urgency of finding a way to treat such an unmet medical need and bringing it to patients as soon as possible.</p>\n<p>\"There is a continued dialogue with the FDA. I wouldn't be able to speculate what the outcome of this dialogue will be,\" he said.</p>\n<p>\"Our trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let's keep fingers crossed,\" he added.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHVF":"Roche Holding Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153622308","content_text":"ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheimer's disease with the U.S. Food and Drug Administration (FDA) as clinical trials proceed, Chief Executive Severin Schwan told reporters on Thursday.\nAnalysts have speculated about an expedited filing for regulatory approval of gantenerumab, which could be a blockbuster if shown to work against the debilitating disease.\nRoche will complete a Phase-III trial of the medicine in the second half of next year, Schwan said, citing the urgency of finding a way to treat such an unmet medical need and bringing it to patients as soon as possible.\n\"There is a continued dialogue with the FDA. I wouldn't be able to speculate what the outcome of this dialogue will be,\" he said.\n\"Our trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let's keep fingers crossed,\" he added.","news_type":1},"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
